je.st
news
Tag: mercks
Mercks Investigational Beta-lactamase Inhibitor Relebactam (MK-7655) Granted Qualified Infectious Disease Product (QIDP) and Fast Track Designations by FDA
2014-09-04 15:00:00| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has designated relebactam (previously known as MK-7655), the companys investigational beta-lactamase inhibitor, as a Qualified Infectious Disease Product (QIDP) with designated Fast Track status. Language: English Contact: Media:Caroline Lappetito, 267-305-7639orRobert Consalvo, 908-423-6595orInvestors:Joseph Romanelli, 908-423-5185orJustin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: product
fast
track
disease
CHMP Issues Positive Opinion for Intravenous (IV) Formulation of Mercks NOXAFIL (posaconazole)
2014-07-30 14:00:03| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J., July 30, 2014 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a new, investigational intravenous (IV) formulation of NOXAFIL (posaconazole). Language: English read more
Tags: issues
positive
opinion
formulation
Mercks HIV Campaign, I Design, Partners with Music Industry Promoter and HIV Advocate Maria Davis and Positive Womens Network - USA to Encourage Women Living with HIV to be Vocal about their Treatment
2014-07-17 14:40:36| Merck.com - Corporate News
Dateline City: WHITEHOUSE STATION Speaking Up is Vital, Given the Significant Impact of the Disease on Women WHITEHOUSE STATION, N.J., July 17, 2014 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that Maria Davis a music industry promoter and HIV advocate and Positive Womens Network USA (PWN-USA) are joining its national HIV education campaign, I Design. The awareness campaign will help inspire and motivate women living with HIV to vocalize how they are feeling on their treatment plans, and to work with their healthcare teams to design treatment plans specific to their individual health needs. Language: English Multimedia read more
EU Picks Up Mercks Pest Repellent\n
2014-07-02 07:00:00| Happi Breaking News
Mercks Investigational Anti-PD-1 Antibody, Pembrolizumab, Under Regulatory Review in Europe for the Treatment of Advanced Melanoma
2014-06-30 12:00:00| Merck.com - Research & Development News
Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for pembrolizumab (MK-3475), the companys investigational anti-PD-1 antibody, for the treatment of advanced melanoma. If approved by the European Commission (EC), pembrolizumab has the potential to be the first anti-PD-1 therapy in Europe. Language: English Contact: Media:Steve Cragle, 973-432-4781Claire Mulhear, 908-423-7425orInvestors:Joseph Romanelli, 908-423-5185Justin Holko, 908-423-5088 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: advanced
review
europe
treatment
Sites : [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] next »